Sarepta Therapeutics Outlines 2026 Priorities on Strong Cash Position WS Q1 2026 Earnings EPS Misses Estimates by 39 Revenue Not Disclosed Space Stocks Slide as Blue Origin Rocket Explosion and SpaceX Valuation Concerns Weigh on Sector